CI
BCRX icon

CX Institutional’s BioCryst Pharmaceuticals BCRX Stock Holding History

CX Institutional’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,760
Closed -$19K – 515
2022
Q2 		$19K Buy
+1,760
New +$18.2K ﹤0.01% 849

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CX Institutional's BCRX Position: Q3 2022 in Review

CX Institutional sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 1,760 shares — an estimated $19K sold.

CX Institutional first reported a position in BCRX in Q2 2022 and held it in 1 quarter. The position peaked at $19K in Q2 2022. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • CX Institutional reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CX Institutional sold 1,760 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $19K.
  • CX Institutional first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • CX Institutional's BioCryst Pharmaceuticals position peaked at $19K in Q2 2022.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on CX Institutional's 13F filing for Q3 2022, filed 4 Nov 2022.